A novel Bayesian dose-escalation Phase Ib study design investigating combination of the mammalian target of rapamycin (mTOR) inhibitor RAD001 with standard chemotherapy in patients with lung cancer

Di Scala, Lilla1 Pylväniäinen, Ilona1 Molloy, Betty1 Kunz, Tiffany2 Miller, Neil1 Proot, Pieter3 Dimitrijevic, Sasa1 Zuber, Emmanuel1

1 Novartis Oncology, Basel, Switzerland 2 Novartis Oncology, East Hanover, NJ, USA 3 Novartis Pharma, Basel, Switzerland

Background: RAD001C (everolimus) is an oral inhibitor of mammalian target of rapamycin (mTOR) with anti-tumor activity. As single-agent and in combination with other anticancer agents, RAD001C showed efficacy in in vitro and in vivo NSCLC models. RAD001C is currently being investigated in clinical trials as an anticancer agent in patients with advanced lung cancer. In a phase I study, 4 disease stabilizations (SD) and 1 partial response (PR), as per RECIST, were reported from 14 NSCLC patients treated with RAD001C monotherapy. Further phase Ib studies have been designed to investigate the feasibility of different regimens combining RAD001 doses and schedules with selected standard chemotherapeutic agents in patients with advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). A novel statistical design was tailored to optimize the regimen selection in this combination phase Ib setting.

Methods: Three phase I, open-label, multi-center studies of RAD001 with standard chemotherapy in patients with advanced NSCLC or SCLC are designed as an adaptive Bayesian dose-escalation scheme. This is based on a Time-to-DLT (Dose Limiting Toxicity) model estimating the risk that patients experience a DLT within their first cycle of treatment (as primary endpoint) or at any other time-point during the study. This novel statistical design improves on the traditional phase I designs. The adaptive nature of the Bayesian methodology allows the DLT rate to be re-evaluated at any time during the study, allowing quicker intervention following toxicity events, without the constraint of fixed-size cohorts of patients. Decision-making takes into account all available information from all patients in the study thanks to the time-to-event model. All toxicities occurring at any time during treatment are incorporated. In this phase Ib combination setting, the knowledge already available on the safety profile of the individual agents allows to make full use of the Bayesian methodology to identify the optimal dose (in terms of toxicity profile) for future studies. DLT rates are provided with model-based confidence intervals. The way the design operates has been investigated under a variety of toxicity scenarios. In particular, the risk to choose too high (too toxic) or too low a dose has been calculated and discussed versus traditional designs.

Results: Studies are ongoing. Results will be provided as available with a discussion of advantages and disadvantages of the novel phase I study design.

Conclusions: This adaptive phase Ib study design may be considered as a better decision-making tool which can exploit all safety information available and ensure higher confidence in the regimen selected for later phase clinical studies.

P3-027 NT: Molecular Therapeutics Posters, Wed, Sept 5 – Thur, Sept 6

Anti-tumor efficacies of liposomal honokiol combined with cisplatin in lewis lung cancer and human a 549 lung cancer models

Jiang, Qiqi1,2 Fan, Lin-Yu1 Yang, Guang-Li1 Tang, Min-Hai2 Ye, Hao-Yu1 Hou, Wen-Li1 Hu, Jia1 Zhong, Zheng-Hua1 Chen, Xiang2 Xu, Yong-Bing1 Li, Xia1 Chen, Li-Juan2 Nie, Xiu-Hong1 Zhi, Xiuyi1 Wei, Yu-Quan1

1 Xuan Wu Lung Cancer Center, Xuan Wu Hospital of Capital Medical University, Beijing, China 2 State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China 3 School of Pharmacy, Sichuan University, Chengdu, China 4 School of Chemical and Bioengineering, Sichuan University, Sichuan, China 5 School of Life Science, Sichuan University, Chengdu, China

Purpose: To fully explore the clinical possibility of honokiol, we encapsulated honokiol with long circulating liposome to improve its solubility and prolong its circulation time in body. The potential to increase the anti-tumor effect of liposomal honokiol by combination with cisplatin and possible mechanism have been investigated in in vitro and in vivo.

Experimental Design: Honokiol was encapsulated with long circulating modified liposomes. The pharmacokinetic study and biodistribution of liposomal honokiol in tumor-bearing mice was detected by high performance liquid chromatography. Inhibition of cell proliferation and induction of apoptosis by liposomal honokiol were tested in vitro. In vivo study, LL/2 tumor model and human A549 tumor models were established in C57BL/6N mice and athymic nude mice, respectively. Mice were treated with PBS group, liposomal honokiol, free liposome, cisplatin, and liposomal honokiol plus cisplatin. Tumor volume and survival time were observed and the mechanisms underlying the anti-tumor effect was investigated by detecting the microvessel density, apoptosis in tumor tissue.

Results: Liposomal honokiol has shown remarkable improvement of water solubility and could be dissolved in PBS for i.p injection.